See more : EQRx, Inc. (EQRXW) Income Statement Analysis – Financial Results
Complete financial analysis of WuXi AppTec Co., Ltd. (603259.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of WuXi AppTec Co., Ltd., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Enma Al Rawabi Investment & Real Estate Development Company (9521.SR) Income Statement Analysis – Financial Results
- Kakao Games Corp. (293490.KQ) Income Statement Analysis – Financial Results
- Salzer Electronics Limited (SALZERELEC.NS) Income Statement Analysis – Financial Results
- Elemental Altus Royalties Corp. (ELEMF) Income Statement Analysis – Financial Results
- Kingsrose Mining Limited (KRM.AX) Income Statement Analysis – Financial Results
WuXi AppTec Co., Ltd. (603259.SS)
About WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 40.34B | 39.35B | 22.90B | 16.54B | 12.87B | 9.61B | 7.77B | 6.12B | 4.88B | 4.14B |
| Cost of Revenue | 23.73B | 24.68B | 14.59B | 10.25B | 7.86B | 5.82B | 4.52B | 3.62B | 3.20B | 2.62B |
| Gross Profit | 16.61B | 14.68B | 8.31B | 6.28B | 5.01B | 3.79B | 3.25B | 2.49B | 1.69B | 1.52B |
| Gross Profit Ratio | 41.18% | 37.30% | 36.28% | 37.99% | 38.95% | 39.45% | 41.83% | 40.76% | 34.55% | 36.78% |
| Research & Development | 1.44B | 1.61B | 942.24M | 693.26M | 590.39M | 436.53M | 305.65M | 214.36M | 143.12M | 129.61M |
| General & Administrative | 905.56M | 927.22M | 766.15M | 508.56M | 509.14M | 395.51M | 317.20M | 314.81M | 217.07M | 694.92M |
| Selling & Marketing | 188.00M | 731.59M | 698.97M | 588.46M | 438.54M | 337.88M | 291.51M | 200.44M | 185.81M | 132.15M |
| SG&A | 3.56B | 1.66B | 1.47B | 1.10B | 947.68M | 733.39M | 608.71M | 515.25M | 402.87M | 827.07M |
| Other Expenses | -558.62M | 1.66B | 1.24B | 1.16B | 855.14M | 611.75M | 132.03M | 97.57M | 29.67M | 110.09M |
| Operating Expenses | 4.74B | 4.93B | 3.65B | 2.95B | 2.39B | 1.83B | 1.49B | 1.25B | 1.18B | 829.84M |
| Cost & Expenses | 28.47B | 29.61B | 18.24B | 13.20B | 10.25B | 7.65B | 6.00B | 4.88B | 4.38B | 3.45B |
| Interest Income | 489.93M | 190.85M | 191.69M | 92.36M | 88.21M | 12.19M | 7.89M | 12.02M | 10.90M | 182.68M |
| Interest Expense | 120.28M | 159.84M | 128.33M | 196.03M | 128.02M | 92.41M | 48.55M | 16.36M | 28.13M | 0.00 |
| Depreciation & Amortization | 2.28B | 1.92B | 1.48B | 1.14B | 813.56M | 649.76M | 98.66M | 71.42M | 326.93M | -154.24M |
| EBITDA | 14.17B | 12.79B | 7.75B | 4.81B | 3.26B | 3.25B | 1.79B | 1.52B | 1.16B | 692.75M |
| EBITDA Ratio | 35.12% | 32.46% | 31.61% | 27.87% | 25.83% | 33.68% | 28.36% | 29.11% | 24.28% | 17.10% |
| Operating Income | 11.87B | 10.65B | 6.04B | 3.39B | 2.34B | 2.58B | 1.46B | 1.28B | 771.68M | 861.96M |
| Operating Income Ratio | 29.43% | 27.07% | 26.36% | 20.50% | 18.19% | 26.89% | 18.81% | 21.00% | 15.80% | 20.82% |
| Total Other Income/Expenses | -40.29M | -33.77M | -22.12M | -20.11M | -3.96M | -3.88M | 132.03M | 97.57M | 29.67M | 106.73M |
| Income Before Tax | 11.83B | 10.62B | 6.02B | 3.37B | 2.34B | 2.58B | 1.59B | 1.38B | 801.35M | 968.69M |
| Income Before Tax Ratio | 29.33% | 26.98% | 26.27% | 20.38% | 18.16% | 26.85% | 20.51% | 22.60% | 16.41% | 23.40% |
| Income Tax Expense | 2.13B | 1.72B | 879.66M | 383.13M | 425.56M | 247.14M | 295.90M | 261.20M | 117.57M | 160.58M |
| Net Income | 9.61B | 8.81B | 5.10B | 2.96B | 1.85B | 2.26B | 1.23B | 974.98M | 348.97M | 461.50M |
| Net Income Ratio | 23.81% | 22.40% | 22.26% | 17.90% | 14.41% | 23.51% | 15.80% | 15.94% | 7.15% | 11.15% |
| EPS | 3.27 | 3.01 | 1.75 | 1.06 | 0.68 | 0.95 | 0.56 | 0.46 | 0.17 | 0.22 |
| EPS Diluted | 3.24 | 2.82 | 1.73 | 1.04 | 0.67 | 0.94 | 0.55 | 0.46 | 0.17 | 0.22 |
| Weighted Avg Shares Out | 2.94B | 2.93B | 2.91B | 2.80B | 2.73B | 2.39B | 2.20B | 2.12B | 2.10B | 2.13B |
| Weighted Avg Shares Out (Dil) | 2.97B | 3.13B | 2.95B | 2.84B | 2.78B | 2.40B | 2.22B | 2.12B | 2.10B | 2.13B |
Source: https://incomestatements.info
Category: Stock Reports